Vertaling van "postmenopausal women and men " (Frans → Nederlands) :

Guidelines for the diagnosis and manegement of osteoporosis in postmenopausal women and men from the age of 50 years in the UK.
Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK.

Risks and benefits of estrogen plus progestin in healthy postmenopausal women : principal results From the Women’s Health Initiative randomized controlled trial.
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial.

Arch Intern Med 2006; 166:357-65. Vickers MR, MacLennan AH, Lawton B et al. Main morbidities recorded in the women’s international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women.
Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial.

Bon à savoir: traitement de substitution hormonale et risque de cancer du sein invasif. Folia Pharmacotherapeutica 2011; 38:4-5. [http ...]
Anderson GL, Limacher M, Assaf AR et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy : the Women’s Health Initiative randomized controlled trial.
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial.

JAMA 2005; 293:330-9. Lethaby A, Hogervorst E, Richards M, Yesufu A, Yaffe K. Hormone replacement therapy for cognitive function in postmenopausal women.
JAMA 2005; 293:330-9 Lethaby A, Hogervorst E, Richards M, Yesufu A, Yaffe K. Hormone replacement therapy for cognitive function in postmenopausal women.

49. NICE. Bisphosphonates (alendronate, etidronate, risedronate), selective oestrogen receptor modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women.
hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women.

· Women surveyed were more likely to consider “maintaining relationships with family or friends” as a challenge compared to men [47 percent versus 31 percent]
Women surveyed were more likely to consider “maintaining relationships with family or friends” as a challenge compared to men (47 percent versus 31 percent)

Also, women were less likely than men to feel that they have enough support to take care of themselves and their own needs [60 percent versus 76 percent]
Also, women were less likely than men to feel that they have enough support to take care of themselves and their own needs(60 percent versus 76 percent)

· Women surveyed were more likely to worry “all the time” compared to men [13 percent versus 3 percent].
Women surveyed were more likely to worry “all the time” compared to men [13 percent versus 3 percent].